All Articles

Arlo Technologies smashed expectations with record revenue, fueled by a masterful pivot to recurring services that now form the core of its business.

The nation's only public parking firm faces an insider offer, placing a special committee at the center of a high-stakes test for shareholder value.

The software supply chain firm's Q2 results beat estimates, with cloud revenue soaring 53% as its security platform becomes essential for the AI era.

PAR Technology's Q2 results reveal soaring profitability and 19% revenue growth, prompting a raised 2026 outlook fueled by its AI-driven platform.

Sprout Social's stellar Q2 profit beat isn't just a good quarter; it's a strategic overhaul. A look at its high-stakes bet on enterprise clients and AI.

After two years of losses, Silvaco is back in the black. A deep dive into the AI strategy and key partnerships with NVIDIA, Micron, and Dassault driving its comeback.

Octave Specialty Group's core insurance unit saw 77% revenue growth, fueled by strategic buys and a new AI underwriting platform that signals a tech-led future.

Zentalis Pharmaceuticals is pursuing a dual strategy for its ovarian cancer drug, azenosertib, aiming for fast market entry while securing long-term validation.

Artiva Biotherapeutics secures FDA fast-track status for its novel NK cell therapy, AlloNK. This could revolutionize autoimmune care for millions.

Kodiak AI posts strong Q2 growth and unveils its Gen7 platform, accelerating its push for driverless long-haul. But can revenue outpace a steep cash burn?

With its lead obesity drug in late-stage trials and a Novo Nordisk veteran newly hired, Structure Therapeutics is making a calculated play for the oral GLP-1 crown.

electroCore posts strong Q2 growth and raises guidance, driven by a federal market focus. But as the company maps a path to profitability, a closer look reveals a race between strategic execution and a dwindling cash runway.

NATR's Q2 results show a firm investing heavily in its digital future, with soaring e-commerce sales and subscription growth offsetting currency and China woes.

With a $250M decision pending and a major acquisition closing, Zymeworks is betting its future on a radical pivot to a diversified, revenue-generating model.

Beyond the mixed GAAP results, ICU Medical’s strong non-GAAP growth and raised guidance reveal a company thriving after a strategic pivot.

Apyx Medical's Q2 results show a 28% surge in its aesthetics unit, driven by the new AYON system. Is this strategic pivot away from OEM the key to its future?

A new press release touts 'simplicity' as the future of digital entertainment. But for online gaming platform Mr Win77, are the real complexities hidden?

With nearly $1B in cash and a shrinking net loss, Janux is pushing its advanced prostate cancer drugs while its novel autoimmune therapy nears a key data reveal.

Outset Medical's Q2 results reveal a pivotal moment: a major HCA deal and stronger margins point to a new phase of sustainable growth in the dialysis market.

With a $215M war chest and a runway into 2028, Corvus Pharmaceuticals is aggressively advancing its lead drug, soquelitinib, across cancer and immune diseases.